Subtitle
Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.
44 patients with high-risk (n = 39) or intermediate-risk (n = 5) neuroblastoma were treated with protons. With a median follow-up of 27.6 months, eight patients developed progression including local recurrence (n =1) or distant metastases (n = 7). At three years, the estimated local control, distant metastatic free survival, progression free survival, and overall survival was 97.7, 84.1, 81.8, and 90.9%, respectively.